drugset / Trial / NCT00072930
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objectives of this study are: 1. To explore the antitumor activity of MEDI-522 in combination with docetaxel, prednisone, and zoledronic acid in patients with metastatic Androgen-Independent Prostate Cancer (AIPC); and 2. To summarize the safety of MEDI-522 in combination with docetaxel, prednisone, and zoledronic acid in this patient population.
Timeline
- Start
- 2003-12
- Primary completion
- 2007-04
- Completion
- 2007-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | etaracizumab | Monoclonal antibody | — | Intravenous |
| Background | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Background | Prednisone | Other / unclassified | 3 mg | Intravenous |
| Background | Prednisone | Other / unclassified | 4 mg | Intravenous |
| Background | Zoledronic acid | Other / unclassified | 5 mg | — |